Thyrotropin releasing hormone uptake into serum and cerebrospinal fluid following intravenous or subcutaneous administration. 1988

B R Brooks, and N Kalin, and D A Beaulieu, and C Barksdale, and R L Sufit, and D G Dills
Neurology Service, William S. Middleton Memorial Veterans Administration Hospital, Madison, Wisconsin 53705.

Intravenous thyrotropin releasing hormone (TRH) was administered to 6 amyotrophic lateral sclerosis (ALS) patients at the dose rate of 10 mg/kg. Blood samples were obtained prior to and at 10, 20, 40, 60, and 120 min during the TRH infusions. Lumbar punctures were performed at 90 min following the start of infusion. The mean serum TRH concentration rose from 0.03 +/- 0.02 (SD) to 17 +/- 2 ng/ml by 60 min and remained constant to 120 min. The mean CSF TRH concentration rose 10-fold from 0.02 +/- 0.01 to 0.2 +/- 0.02 ng/ml at 90 min and increased further to 0.5 +/- 0.2 ng/ml at 120 min. Subcutaneous TRH was administered to 4 ALS patients at 2.5 mg/kg and to 5 ALS patients at 5.0 mg/kg. The mean serum TRH concentration increased to 1.4 +/- 0.6 ng/ml (2.5 mg/kg) and 3.2 +/- 1.1 ng/ml (5.0 mg/kg) by 60 min. The mean CSF TRH concentration at 60 min increased to 0.3 +/- 0.08 ng/ml following 2.5 mg/kg TRH and 0.8 +/- 0.04 ng/ml following 5.0 mg/kg TRH. TRH entry into the CSF is comparable following subcutaneous or intravenous administration.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000690 Amyotrophic Lateral Sclerosis A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94) ALS - Amyotrophic Lateral Sclerosis,Lou Gehrig Disease,Motor Neuron Disease, Amyotrophic Lateral Sclerosis,Amyotrophic Lateral Sclerosis With Dementia,Amyotrophic Lateral Sclerosis, Guam Form,Amyotrophic Lateral Sclerosis, Parkinsonism-Dementia Complex of Guam,Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex 1,Charcot Disease,Dementia With Amyotrophic Lateral Sclerosis,Gehrig's Disease,Guam Disease,Guam Form of Amyotrophic Lateral Sclerosis,Lou Gehrig's Disease,Lou-Gehrigs Disease,ALS Amyotrophic Lateral Sclerosis,Amyotrophic Lateral Sclerosis Parkinsonism Dementia Complex 1,Amyotrophic Lateral Sclerosis, Parkinsonism Dementia Complex of Guam,Disease, Guam,Disease, Lou-Gehrigs,Gehrig Disease,Gehrigs Disease,Sclerosis, Amyotrophic Lateral

Related Publications

B R Brooks, and N Kalin, and D A Beaulieu, and C Barksdale, and R L Sufit, and D G Dills
November 1979, American journal of obstetrics and gynecology,
B R Brooks, and N Kalin, and D A Beaulieu, and C Barksdale, and R L Sufit, and D G Dills
January 1985, Journal of perinatal medicine,
B R Brooks, and N Kalin, and D A Beaulieu, and C Barksdale, and R L Sufit, and D G Dills
January 1976, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
B R Brooks, and N Kalin, and D A Beaulieu, and C Barksdale, and R L Sufit, and D G Dills
June 1983, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
B R Brooks, and N Kalin, and D A Beaulieu, and C Barksdale, and R L Sufit, and D G Dills
November 1990, Biological psychiatry,
B R Brooks, and N Kalin, and D A Beaulieu, and C Barksdale, and R L Sufit, and D G Dills
January 1975, Endokrynologia Polska,
B R Brooks, and N Kalin, and D A Beaulieu, and C Barksdale, and R L Sufit, and D G Dills
April 1973, Lancet (London, England),
B R Brooks, and N Kalin, and D A Beaulieu, and C Barksdale, and R L Sufit, and D G Dills
January 1993, The Journal of neuropsychiatry and clinical neurosciences,
B R Brooks, and N Kalin, and D A Beaulieu, and C Barksdale, and R L Sufit, and D G Dills
January 1994, Drug metabolism and disposition: the biological fate of chemicals,
B R Brooks, and N Kalin, and D A Beaulieu, and C Barksdale, and R L Sufit, and D G Dills
February 1986, Neurology,
Copied contents to your clipboard!